These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12410858)

  • 21. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM; Keane WF; Zhang Z; Lyle PA; Appel GB; McGill JB; Parving HH; Cooper ME; Shahinfar S; Brenner BM
    Diabetes Care; 2008 Mar; 31(3):445-7. PubMed ID: 18070995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
    Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
    Brenner BM; Cooper ME; de Zeeuw D; Grunfeld JP; Keane WF; Kurokawa K; McGill JB; Mitch WE; Parving HH; Remuzzi G; Ribeiro AB; Schluchter MD; Snavely D; Zhang Z; Simpson R; Ramjit D; Shahinfar S;
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):328-35. PubMed ID: 11967819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
    Parving HH; de Zeeuw D; Cooper ME; Remuzzi G; Liu N; Lunceford J; Shahinfar S; Wong PH; Lyle PA; Rossing P; Brenner BM
    J Am Soc Nephrol; 2008 Apr; 19(4):771-9. PubMed ID: 18199798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD; Sandoz MS; Keusch GW
    Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
    Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
    Seng WK; Hwang SJ; Han DC; Teong CC; Chan J; Burke TA; Carides GW; Choi YJ
    Nephrology (Carlton); 2005 Oct; 10(5):520-4. PubMed ID: 16221106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
    González F F; Fuentes C V; Castro H C; Santelices L JP; Lorca H E
    Rev Med Chil; 2009 May; 137(5):634-40. PubMed ID: 19701552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
    Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.